Chronic Lymphocytic Leukemia - CLL Ppts and Publications

Acute  Lymphocytic Leukemia
by: Heidi  Borgens & Mary Takagi
http://www.plu.edu/~borgenhl/doc/seminar-project.ppt

Overview  of Diagnostic &  Prognostic Factors for  CLL
by Laura  Rassenti, PhD
http://bcrf.ucsd.edu/events/Presentations/LZR_CLL42305V2.ppt

Leukemia
http://www.hawaii.edu/medtech/MEDT451/Leukemia_files/Leukemia.ppt

Clinical  Implications Of TNF  Family In Blood Disorders
by Dheeraj  Mohania
http://www.pitt.edu/~super7/30011-31001/30241.ppt

Chronic Lymphocytic Leukemia CLL
http://www.austincc.edu/mlt/hem/hemlectunit20chronicleukemias.ppt

Chronic  Myelogenous  Leukemia
http://imrp.ouhsc.edu/sites/oumedicine/uploads/images/CML.ppt

Refractory CLL:  Treatment Approaches 
by George  Ansstas, MD
http://hematology.wustl.edu/conferences/presentations/Ansstas20091002.ppt

Latest 50 Published articles

1. ON 01910.Na is selectively cytotoxic for Chronic Lymphocytic Leukemia cells through a dual mechanism involving PI3K/AKT inhibition and induction of oxidative stress.
2. MicroRNA-130a targets ATG2B and DICER1 to inhibit autophagy and trigger killing of chronic lymphocytic leukemia cells.
3. MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia.
4. Increased CD39 expression on CD4(+) T lymphocytes has clinical and prognostic significance in chronic lymphocytic leukemia.
5. Progress in rearch on allogeneic hematopoietic stem cell transplantation for chronic lymphocytic leukemia.
6. Overrepresentation of specific gene segments of expressed immunoglobulin heavy chain variable region among unmutated and mutated patients with chronic lymphocytic leukemia.
7. Chronic Lymphocytic Leukemia Associated with Immunotactoid Glomerulopathy: A Case Report of Successful Treatment with High-Dose Methyl-Prednisolone in Combination with Rituximab Followed by Alemtuzumab.
8. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: Does donor T-cell engraftment 3 months after transplantation predict survival?
9. Expression of stereotyped B-cell receptor and its clinical value in chronic lymphocytic leukemia.
10. High expression of hematopoietic cell specific Lyn substrate-1 (HS1) predicts poor survival of B-cell chronic lymphocytic leukemia patients.
11. Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention?
12. Chronic Lymphocytic Leukemia Is Associated With Decreased Survival of Patients With Malignant Melanoma and Merkel Cell Carcinoma in a SEER Population-Based Study.
13. Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial.
14. The Aurora A and B kinases are upregulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets.
15. Chronic lymphocytic leukemia revealed by a branulomatous zosteriform eruption.
16. Immune Thrombocytopenia in patients with Chronic Lymphocytic Leukemia is associated with Stereotyped B-Cell Receptors.
17. Invasive ductal carcinoma and chronic lymphocytic leukemia: a unique case of collision tumor in breast.
18. Down-regulated Dicer expression predicts poor prognosis in chronic lymphocytic leukemia.
19. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL).
20. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild type chronic lymphocytic leukemia.
21. ERIC recommendations on TP53 mutation analysis in Chronic Lymphocytic Leukemia.
22. Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features.
23. A role for Danazol in chronic lymphocytic leukemia.
24. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
25. The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells.
26. Pathologic and molecular genetic features of chronic lymphocytic leukemia.
27. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia.
28. Role of ofatumumab in treatment of chronic lymphocytic leukemia.
29. The Importance of IGHV Mutational Status in del(11q) and del(17p) Chronic Lymphocytic Leukemia.
30. Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia.
31. Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.
32. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
33. RNA-based markers as prognostic factors in chronic lymphocytic leukemia.
34. Is bendamustine an ideal partner for rituximab in the management of relapsed chronic lymphocytic leukemia? Results of a multicenter Phase II trial.
35. Composite Hodgkin lymphoma and chronic lymphocytic leukemia: A rare case.
36. A Randomized, Controlled Trial of Panax quinquefolius Extract (CVT-E002) to Reduce Respiratory Infection in Patients With Chronic Lymphocytic Leukemia.
37. Specific p53 mutations do not impact results of alemtuzumab therapy among chronic lymphocytic leukemia patients.
38. An Increased Number of Individuals with Clinically Recognized Monoclonal B-Cell Lymphocytosis Characterizes a Recent Database of Chronic Lymphocytic Leukemia Rai Stage 0.
39. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse.
40. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.
41. A comparative analysis of cutaneous marginal zone lymphoma and cutaneous chronic lymphocytic leukemia.
42. Individualized Fludarabine-Based Regimen in Elderly Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
43. Genetics: Splicing the pieces of the chronic lymphocytic leukemia puzzle.
44. Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia.
45. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiological parameters.
46. Improving quality of life in chronic lymphocytic leukemia.
47. Reciprocal changes in regulatory T cells and Th17 helper cells induced by exercise in patients with chronic lymphocytic leukemia.
48. Priapism as an initial presentation of chronic lymphocytic leukemia.
49. SOCS1 is significantly up-regulated in Nutlin-3-treated p53(wild-type) B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155.
50. Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?